Compass Therapeutics(CMPX) - 2024 Q4 - Annual Results

Financial Position - Estimated cash, cash equivalents, and marketable securities were approximately $127 million as of December 31, 2024[6] - The financial data is unaudited and preliminary, subject to completion of financial closing procedures[6] Product Development - The company announced the advancement of a new drug candidate[5]